See more : Edoc Acquisition Corp. (ADOCW) Income Statement Analysis – Financial Results
Complete financial analysis of Astec LifeSciences Limited (ASTEC.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Astec LifeSciences Limited, a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- ME Renewable Power Corporation (MEPW) Income Statement Analysis – Financial Results
- Molecular Energies PLC (PPCGF) Income Statement Analysis – Financial Results
- WenYi Trinity Technology Co., Ltd (600520.SS) Income Statement Analysis – Financial Results
- HUB Security (HUB.TA) Income Statement Analysis – Financial Results
- Property Solutions Acquisition Corp. II (PSAGU) Income Statement Analysis – Financial Results
Astec LifeSciences Limited (ASTEC.NS)
About Astec LifeSciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures, distributes, and sells agrochemicals active ingredients and pharmaceutical intermediates in India. It manufactures a range of fungicides, insecticides, herbicides, and intermediates, such as triazole fungicides, heterocyclic herbicides, sulfonyl urea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, and silane derivatives; fluorinated aromatic amines, pyridine derivatives, aromatic carboxylic acids, benzyl alcohols, ketones and benzophenones, and heterocyclic mercaptans; fluorinated aromatic, aliphatic, and heterocyclic intermediates; heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, heterocyclic sulfonyl chlorides, heterocyclic sulphonamides, heterocyclic carbamates, thiourium salts, alkyl and aryl chloroformates, substituted pyrimidine diones, and pyrazolones; and substituted 1,2- and 1,3- pyrimidines. The company's products also comprise pyrazolyl aromatic ketones, morpholine derivatives, aromatic azo compounds, substituted triazines, imidate ethers, mesylated intermediates, substituted epoxides, ketals and bromo ketals, aromatic and aliphatic ethers, cyclopropyl ethers, cyclopropyl aldehydes and ketones, conjugated ketones, acetophenone derivatives, pinacolone derivatives, aliphatic and aromatic carboxylic acids, aliphatic and aromatic acid chlorides, halogenated and non-halogenated anhydrides, aliphatic alkenes, and halo alkanes; and aliphatic and aromatic brominated derivatives, cyanides, esters, carboxamides, amines, and alcohols and diols. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.58B | 6.28B | 6.77B | 5.55B | 5.23B | 4.31B | 3.61B | 2.99B | 2.59B | 2.67B | 2.07B | 1.75B | 1.13B | 1.09B | 1.12B | 844.15M | 551.84M |
Cost of Revenue | 3.25B | 4.01B | 3.91B | 3.45B | 3.41B | 2.82B | 2.37B | 1.80B | 1.77B | 1.83B | 1.46B | 1.18B | 776.76M | 851.76M | 795.74M | 568.68M | 339.91M |
Gross Profit | 1.33B | 2.27B | 2.86B | 2.10B | 1.82B | 1.49B | 1.24B | 1.19B | 823.65M | 839.64M | 613.67M | 569.69M | 351.69M | 242.67M | 323.68M | 275.46M | 211.93M |
Gross Profit Ratio | 29.09% | 36.12% | 42.23% | 37.79% | 34.81% | 34.61% | 34.35% | 39.75% | 31.77% | 31.50% | 29.65% | 32.60% | 31.17% | 22.17% | 28.92% | 32.63% | 38.40% |
Research & Development | 27.00M | 14.85M | 9.14M | 9.22M | 8.91M | 8.72M | 8.59M | 5.53M | 2.81M | 5.95M | 2.75M | 4.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 71.36M | 122.56M | 81.42M | 66.04M | 73.58M | 44.94M | 47.15M | 52.36M | 49.93M | 125.43M | 31.69M | 16.28M | 0.00 | 46.06M | 37.27M | 38.05M | 38.33M |
Selling & Marketing | 26.29M | 75.10M | 108.34M | 62.98M | 55.78M | 38.71M | 53.99M | 1.55M | 0.00 | 9.04M | 24.68M | 47.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 97.64M | 197.67M | 189.75M | 129.01M | 129.36M | 83.66M | 101.14M | 53.90M | 49.93M | 134.46M | 56.37M | 168.40M | 0.00 | 46.06M | 37.27M | 38.05M | 38.33M |
Other Expenses | 1.22B | 130.60M | 3.28M | 47.00K | 2.42M | 1.20M | 812.00K | 617.74M | 642.76M | 424.41M | 536.10K | 2.02M | 102.30K | 96.64M | 73.04M | 53.70M | 38.19M |
Operating Expenses | 1.35B | 1.84B | 1.65B | 1.20B | 1.14B | 806.11M | 676.71M | 677.17M | 692.69M | 424.41M | 407.08M | 418.35M | 281.70M | 142.69M | 110.32M | 91.75M | 76.52M |
Cost & Expenses | 4.99B | 5.86B | 5.56B | 4.65B | 4.54B | 3.62B | 3.05B | 2.48B | 2.46B | 2.25B | 1.86B | 1.60B | 1.06B | 994.46M | 906.06M | 660.44M | 416.43M |
Interest Income | 1.51M | 40.49M | 2.63M | 7.85M | 2.83M | 3.63M | 8.83M | 9.92M | 19.30M | 8.35M | 3.13M | 1.57M | 3.24M | 8.15M | 3.67M | 450.21K | 407.01K |
Interest Expense | 252.26M | 207.14M | 90.58M | 47.51M | 125.94M | 123.76M | 106.60M | 122.35M | 114.95M | 113.70M | 79.17M | 62.33M | 44.65M | 34.43M | 42.87M | 50.46M | 42.28M |
Depreciation & Amortization | 362.53M | 336.53M | 343.56M | 256.55M | 231.64M | 193.49M | 146.82M | 136.82M | 138.48M | 126.87M | 147.67M | 118.74M | 86.38M | 58.30M | 41.64M | 32.67M | 9.49M |
EBITDA | -2.69M | 893.14M | 1.65B | 1.19B | 971.11M | 876.29M | 810.53M | 546.60M | 356.29M | 553.40M | 376.94M | 268.14M | 154.96M | 158.20M | 255.01M | 216.38M | 158.25M |
EBITDA Ratio | -0.06% | 14.22% | 24.06% | 21.50% | 18.60% | 20.90% | 21.29% | 22.16% | 9.32% | 20.10% | 17.39% | 15.06% | 13.98% | 14.46% | 22.78% | 25.63% | 28.68% |
Operating Income | -403.64M | 434.56M | 1.20B | 897.14M | 684.84M | 685.21M | 564.27M | 510.20M | -174.42M | 189.76M | 111.50M | 85.05M | 18.01M | 69.63M | 171.79M | 124.16M | 94.50M |
Operating Income Ratio | -8.81% | 6.92% | 17.79% | 16.17% | 13.10% | 15.90% | 15.62% | 17.08% | -6.73% | 7.12% | 5.39% | 4.87% | 1.60% | 6.36% | 15.35% | 14.71% | 17.12% |
Total Other Income/Expenses | -213.84M | -1.32B | -1.12B | -835.85M | -131.05M | -126.17M | -7.16M | -222.77M | -542.27M | -292.27M | -111.16M | -86.03M | -63.95M | -27.64M | -40.44M | -55.28M | 0.00 |
Income Before Tax | -617.48M | 349.47M | 1.21B | 890.71M | 613.53M | 559.04M | 557.12M | 287.43M | -174.42M | 189.76M | 111.50M | 87.07M | 18.12M | 69.63M | 171.79M | 124.16M | 94.50M |
Income Before Tax Ratio | -13.48% | 5.56% | 17.90% | 16.05% | 11.74% | 12.97% | 15.42% | 9.62% | -6.73% | 7.12% | 5.39% | 4.98% | 1.61% | 6.36% | 15.35% | 14.71% | 17.12% |
Income Tax Expense | -148.57M | 93.53M | 312.43M | 240.02M | 138.25M | 201.39M | 206.74M | 95.64M | 16.23M | 41.93M | 24.98M | 28.05M | 5.38M | 20.86M | 33.37M | 16.86M | 13.75M |
Net Income | -469.30M | 255.65M | 898.59M | 650.49M | 475.11M | 357.37M | 349.04M | 191.18M | -191.64M | 147.75M | 86.76M | 59.51M | 13.65M | 48.98M | 132.12M | 103.75M | 79.45M |
Net Income Ratio | -10.24% | 4.07% | 13.28% | 11.72% | 9.09% | 8.29% | 9.66% | 6.40% | -7.39% | 5.54% | 4.19% | 3.41% | 1.21% | 4.48% | 11.80% | 12.29% | 14.40% |
EPS | -23.93 | 13.04 | 45.87 | 33.23 | 24.29 | 18.28 | 17.88 | 9.81 | -9.85 | 7.91 | 4.74 | 3.45 | 0.81 | 2.89 | 10.98 | 11.00 | 8.42 |
EPS Diluted | -23.93 | 13.04 | 45.85 | 33.21 | 24.27 | 18.26 | 17.84 | 9.78 | -9.82 | 7.91 | 4.74 | 3.43 | 0.81 | 2.89 | 10.98 | 11.00 | 8.42 |
Weighted Avg Shares Out | 19.61M | 19.60M | 19.59M | 19.58M | 19.56M | 19.55M | 19.52M | 19.50M | 19.46M | 18.68M | 18.30M | 17.21M | 16.93M | 16.93M | 12.04M | 9.43M | 9.43M |
Weighted Avg Shares Out (Dil) | 19.61M | 19.61M | 19.60M | 19.59M | 19.57M | 19.58M | 19.57M | 19.54M | 19.52M | 18.68M | 18.30M | 17.35M | 16.93M | 16.93M | 12.04M | 9.43M | 9.43M |
Source: https://incomestatements.info
Category: Stock Reports